Page last updated: 2024-12-06

pholcodine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

pholcodine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pholcodine : A morphinane alkaloid that is a derivative of morphine with a 2-morpholinoethyl group at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311356
CHEMBL ID2105224
CHEBI ID53579
SCHEMBL ID154354
MeSH IDM0053095

Synonyms (80)

Synonym
unii-lpp64awz7l
lpp64awz7l ,
folkodin
pholcodine
glycodine
folcodina [inn-spanish]
hibernyl
weifacodine
pholcodinum [latin]
3-(2-(4-morpholinyl)ethyl)morphine
beta-morpholinoethylmorphine
folcodina [spanish]
lantuss
adaphol
pholtex
morphine, 3-o-(2-morpholinoethyl)-
folcodine
codylin
dea no. 9314
einecs 208-102-9
neocodin
o(sup 3)-(2-morpholinoethyl)morphine
memine
ethnine simplex
tetrahydro-1,4-oxazinylmethylcodeine
7,8-didehydro-4,5-alpha-epoxy-17-methyl-3-(2-morpholinoethoxy)morphinan-6-alpha-ol
folkodin [czech]
morpholinylethylmorphine
pectolin
homocodeine
dia-tuss
tussokon
pholcodinum [inn-latin]
pholcolin
copholco
neocodine
pholcodine [inn:ban]
codisol
pholcodin
morphine, o(sup 3)-(2-morpholinoethyl)-
3-morpholylaethylmorphin [german]
morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-3-(2-morpholinoethoxy)-
pholcodine linctus (tn)
509-67-1
pholcodine (inn)
D07385
CHEBI:53579 ,
3-morpholinoethylmorphine
(5alpha,6alpha)-17-methyl-3-[2-(morpholin-4-yl)ethoxy]-7,8-didehydro-4,5-epoxymorphinan-6-ol
3-(2-morpholinoethyl)morphine
3-morpholylaethylmorphin
pholcodinum
folcodina
biocalyptol
ethnine
CHEMBL2105224
galenphol
galphol
EPITOPE ID:116651
SCHEMBL154354
pholcodine [mi]
morphinan-6-ol, 7,8-didehydro-4,5-epoxy-17-methyl-3-(2-(4-morpholinyl)ethoxy)-, (5.alpha.,6.alpha.)-
pholcodine [inn]
pholcodine [who-dd]
ids-np-011(sect.2)
beta-morpholinylethylmorphine
o3-(2-morpholinoethyl)morphine
prodromine
gtpl9086
covonia dry cough
pavacol-d
(4r,4ar,7s,7ar,12bs)-3-methyl-9-(2-morpholin-4-ylethoxy)-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-o
DB09209
(1s,5r,13r,14s,17r)-4-methyl-10-[2-(morpholin-4-yl)ethoxy]-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-ol
DTXSID70198923
3-o-(2-morpholinoethyl)-morphine
3-morpholylathylmorphin
03-(2-morpholinoethyl)-morphine
Q3124290
(4r,4ar,7s,7ar,12bs)-3-methyl-9-(2-morpholin-4-ylethoxy)-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"2 h) and eliminated slowly with a mean half-life of 50."( Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.
Bochner, F; Chen, ZR; Somogyi, A, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Blood and saliva samples and all urine were collected over 168 h after each dosage administration."( Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.
Bochner, F; Chen, ZR; Somogyi, A, 1988
)
0.27
" The method was successfully applied to the syrup dosage form."( Determination of pholcodine alone or in combination with ephedrine in human plasma using fluorescence spectroscopy.
Belal, F; Elmansi, H; Magdy, G, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antitussiveAn agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic heteropentacyclic compound
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (25.37)18.7374
1990's10 (14.93)18.2507
2000's14 (20.90)29.6817
2010's15 (22.39)24.3611
2020's11 (16.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (8.22%)5.53%
Reviews6 (8.22%)6.00%
Case Studies4 (5.48%)4.05%
Observational1 (1.37%)0.25%
Other56 (76.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Anaphylaxis to Neuromuscular Blocking Agents and Pholcodine Exposure. Case-control Study [NCT02250729]1,020 participants (Anticipated)Interventional2014-07-31Recruiting
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019: a Single-center, Open-label, Parallel-group Randomized Controlled Clinical Trial [NCT05501288]108 participants (Actual)Interventional2022-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]